Cytokinetics, Incorporated announced that CEDAR-HCM, Clinical Evaluation of Dosing with Aficamten to Reduce Obstruction in a Pediatric Population in HCM, a clinical trial of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy, HCM, is open to enrollment. “We are pleased to further expand the broad development program for aficamten with the start of CEDAR-HCM, a trial assessing the safety and efficacy of a cardiac myosin inhibitor in a pediatric population,” said Fady Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics to Hold Annual Meeting of Stockholders
- CYTK Earnings this Week: How Will it Perform?
- Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
- Cytokinetics Appoints Sung H. Lee as New CFO
- Cytokinetics names Sung Lee as CFO